Shilpa Biologicals Pvt Ltd files Type IV DMF of recombinant Human Albumin 20% with USFDA

Shilpa Biologicals Pvt Ltd, a wholly owned subsidiary of SHILPA MEDICARE LIMITED has filed its first Drug Master File of recombinant Human Albumin 20% with USFDA.

This novel recombinant has been developed and is a patented novel recombinant Human Albumin 20% process which is completely-Environment friendly, Consistent High-Quality product, Scalable to massive scales and is cost competitive.

Recombinant Human Albumin 20% targets to fulfil growing demand of human serum albumin to deliver current and growing market demand.

Shares of Shilpa Medicare Limited was last trading in BSE at Rs. 490.00 as compared to the previous close of Rs. 442.60. The total number of shares traded during the day was 21572 in over 2176 trades.

The stock hit an intraday high of Rs. 497.00 and intraday low of 445.65. The net turnover during the day was Rs. 10373605.00.

Source : Equity Bulls

Keywords

ShilpaMedicare INE790G01031 ShilpaBiologicals DMF USFDA RecombinantHumanAlbumin